SequelSEC

MeiraGTx Holdings plc MGTX

Biological Products, (No Diagnostic Substances) · CIK 0001735438 · Fiscal year ends 1231

Revenue
$397.50M
Fiscal year ended 2026-06-30
Operating income
$184.03M
Fiscal year ended 2026-06-30
Free cash flow
$10.47M
Fiscal year ended 2026-06-30

MeiraGTx Holdings plc (MGTX) reported revenue of $397.50M and net income of $78.98M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from MeiraGTx Holdings plc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

MeiraGTx Holdings plc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$397.50M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$184.03M
Net income$78.98M
Research & development$153.16M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$2.36M
Diluted EPS$0.71
Selling, general & administrativeUnavailable
General & administrative$52.16M
Selling & marketingUnavailable

Balance

MeiraGTx Holdings plc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$143.17M
Total assets$396.45M
Current assets$218.35M
Total liabilities$180.67M
Current liabilities$58.10M
Total equity incl. NCI$215.78M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$11.67M

Cash flow

MeiraGTx Holdings plc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$13.69M
Capital expenditures$3.22M
Investing cash flow-$27.53M
Financing cash flow$128.89M
Net change in cashUnavailable
Stock-based compensation$18.99M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$12.10M

Derived

MeiraGTx Holdings plc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$10.47M
Gross marginUnavailable
Operating margin46.3%
FCF margin2.6%
SBC / revenue4.8%
Current ratio3.76x
Revenue YoY growth948.3%
Net margin19.9%
R&D / revenue38.5%
CapEx / revenue0.8%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MGTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.